Switch theme
Sign up to access all valuation multiples
Shenzhen New Industries Biomedical Engineering Co Ltd is researching, developing, producing and selling a series of fully automatic chemiluminescence immunoassay instruments and supporting reagents.
1995
n/a
LTM Revenue $666M
LTM EBITDA $324M
$5.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Snibe has a last 12-month revenue of $666M and a last 12-month EBITDA of $324M.
In the most recent fiscal year, Snibe achieved revenue of $541M and an EBITDA of $282M.
Snibe expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Snibe valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $541M | $634M | XXX | XXX | XXX |
| Gross Profit | $250M | $295M | XXX | XXX | XXX |
| Gross Margin | 46% | 47% | XXX | XXX | XXX |
| EBITDA | $282M | $307M | XXX | XXX | XXX |
| EBITDA Margin | 52% | 48% | XXX | XXX | XXX |
| Net Profit | $134M | $183M | XXX | XXX | XXX |
| Net Margin | 25% | 29% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Snibe's stock price is CNY 53 (or $7).
Snibe has current market cap of CNY 41.4B (or $5.7B), and EV of CNY 38.9B (or $5.4B).
See Snibe trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.4B | $5.7B | XXX | XXX | XXX | XXX | $0.35 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Snibe has market cap of $5.7B and EV of $5.4B.
Snibe's trades at 8.0x LTM EV/Revenue multiple, and 16.5x LTM EBITDA.
Analysts estimate Snibe's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Snibe and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $5.4B | XXX | XXX | XXX |
| EV/Revenue | 8.5x | XXX | XXX | XXX |
| EV/EBITDA | 17.4x | XXX | XXX | XXX |
| P/E | 22.0x | XXX | XXX | XXX |
| P/E/Growth | 1.2x | XXX | XXX | XXX |
| EV/FCF | 28.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSnibe's NTM/LTM revenue growth is 18%
Snibe's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Snibe's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Snibe's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Snibe and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 17% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 48% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 66% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 9% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 28% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Snibe acquired XXX companies to date.
Last acquisition by Snibe was XXXXXXXX, XXXXX XXXXX XXXXXX . Snibe acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Snibe founded? | Snibe was founded in 1995. |
| Where is Snibe headquartered? | Snibe is headquartered in China. |
| Is Snibe publicy listed? | Yes, Snibe is a public company listed on SHE. |
| What is the stock symbol of Snibe? | Snibe trades under 300832 ticker. |
| When did Snibe go public? | Snibe went public in 2020. |
| Who are competitors of Snibe? | Similar companies to Snibe include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Snibe? | Snibe's current market cap is $5.7B |
| What is the current revenue of Snibe? | Snibe's last 12-month revenue is $666M. |
| What is the current EBITDA of Snibe? | Snibe's last 12-month EBITDA is $324M. |
| What is the current EV/Revenue multiple of Snibe? | Current revenue multiple of Snibe is 8.0x. |
| What is the current EV/EBITDA multiple of Snibe? | Current EBITDA multiple of Snibe is 16.5x. |
| What is the current revenue growth of Snibe? | Snibe revenue growth between 2023 and 2024 was 17%. |
| Is Snibe profitable? | Yes, Snibe is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
